The dipeptidyl peptidase IV inhibitors vildagliptin and K-579 inhibit a phospholipase C: a case of promiscuous scaffolds in proteins [v3; ref status: indexed, http://f1000r.es/51m]

The dipeptidyl peptidase IV inhibitors vildagliptin and K-579 inhibit a phospholipase C: a case of promiscuous scaffolds in proteins [v3; ref status: indexed, http://f1000r.es/51m]

The long term side effects of any newly introduced drug is a subject of intense research, and often raging controversies. One such example is the dipeptidyl peptidase-IV (DPP4) inhibitor used for treating type 2 diabetes, which is inconclusively implicated in increased susceptibility to acute pancre...

Full description

Bibliographic Details
Main Authors: Sandeep Chakraborty, Adela Rendón-Ramírez, Bjarni Ásgeirsson, Mouparna Dutta, Anindya S. Ghosh, Masataka Oda, Ravindra Venkatramani, Basuthkar J. Rao, Abhaya M. Dandekar, Félix M. Goñi
Format: Article
Language:English
Published: F1000 Research Ltd 2015-01-01
Series:F1000Research
Subjects:
Biomacromolecule-Ligand Interactions
Endocrine & Metabolic Pharmacology
Online Access:http://f1000research.com/articles/2-286/v3

Internet

http://f1000research.com/articles/2-286/v3

Similar Items